Crispr Therapeutics: Early-Stage Research Updates Show Promise

Summary

• Crispr Therapeutics AG's current revenue from CASGEVY is limited by high costs, profit-sharing, and logistical hurdles, making future pipeline progress critical.
• Management is focused on improving CASGEVY and developing next-generation gene therapies, especially in cardiology and autoimmune diseases, but these are early stage.
• The company faces a highly competitive landscape and will likely need significant dilutive financing to fund long development timelines.
• While the long-term potential is huge, commercial success is uncertain and years away, so I rate CRSP stock a Hold for now.

piyaset/iStock via Getty Images

Introduction

Crispr Therapeutics AG (NASDAQ:CRSP) is a biotech company focused on gene editing through specialized DNA therapy. The company has one approved treatment for cycle cell disease, and four distinct treatments in the pipeline:

These

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.